comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 16:57:04 - browse：1141

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

WSS

Marc Tessier

In rare move, senator releases unverified FBI source report alleging Biden bribe

When a patient nears the end, a feared therapy can comfort

Behind warning on Apellis’s eye drug lies a conflict of interest

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Sanders wants to replace patents with prizes for drug inventions

hotspot

comprehensive

focus

Affirmative action in medical school literally saved lives

As the dark side of IVF slowly comes into focus, even more transparency is needed

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The stock market has soared this year, but will it last? Experts weigh in

Moonlake's readout produced a cash windfall. Risks remain

Judge denies Trump's request for new trial in E. Jean Carroll case

Affirmative action in medical school literally saved lives

Dementia risk linked to living in disadvantaged areas: Study

Hollywood unions extend contract negotiations for actors

Mystery swirls around US soldier who entered North Korea days ago, officials say

hotspot

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

'The boss' wants server deleted: New allegations emerge in Trump indictment

An outrageous hospital charge: I paid $710 for an hour of babysitting

'CMA Fest' 2023: How to watch, who is performing and more

US jobless claims fall again as labor market continues to flash strength

hotspot

hotspot

entertainment

hotspot